Immunotherapy for Infectious Diseases

Production of Igs and MAbs Targeting Infectious Diseases 93
53. Shibata R, et al. Infection and pathogenicity of chimeric simian-human immunodeficiency
viruses in macaques: determinants of high virus loads and CD4 cell killing. J Infect Dis
1997; 176:362–373.
54. Mascola JR, et al. Protection of macaques against vaginal transmission of a pathogenic
HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000;
2:207–210.
55. Mascola JR, et al. Protection of Macaques against pathogenic simian/human immunodeficiency
virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 1999;
73:4009–4018.
56. Baba TW, et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect
against mucosal simian-human immunodeficiency virus infection. Nat Med 2000;
6:1–7.
57. Conley AJ, et al. The consequence of passive administration of an anti-human immunodeficiency
virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees
with a primary virus isolate. J Virol 1996; 70:6751–6758.
58. Poignard P, et al. Neutralizing antibodies have limited effects on the control of established
HIV-1 infection in vivo. Immunity 1999; 10:431–438.
59. Kavanaugh AF. Anti-tumor necrosis factor-alpha monoclonal antibody therapy for rheumatoid
arthritis. Rheum Dis Clin North Am 1998; 24:593–614.
60. Wendling D, et al. A randomized, double blind, placebo controlled multicenter trial of
murine anti-CD4 monoclonal antibody therapy in rheumatoid arthritis. J Rheumatol 1998;
25:1457–1461.
61. Vitali C, Sciuto M, Bombardieri S. Immunotherapy in rheumatoid arthritis: a review. Int
J Artific Organs 1993; 16(suppl 5):196–200.
62. Choy EH, et al. The pharmacokinetics and human anti-mouse antibody response in
rheumatoid arthritis patients treated with a chimeric anti-CD4 monoclonal antibody [letter].
Br J Rheumatol 1998; 37:801–802.
63. Goldenberg MM. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody,
a novel agent for the treatment of metastatic breast cancer. Clin Ther 1999;
21:309–318.
64. McLaughlin P, et al. Clinical status and optimal use of rituximab for B-cell lymphomas.
Oncology 1998; 12:1763–1769; discussion 1769–1770, 1775–1777.
65. Jensen M, et al. Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia
and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab).
Ann Hematol 1998; 77:89–91.
66. Cosimi AB. Clinical development of Orthoclone OKT3. Transplant Proc 1987; 19(2 suppl
1):7–16.
67. Cahn JY, et al. Treatment of acute graft-versus-host disease with methylprednisolone and
cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody. A multicenter
phase III study. Transplantation 1995; 60:939–942.
68. Kovarik J, et al. Disposition and immunodynamics of basiliximab in liver allograft recipients.
Clin Pharmacol Ther 1998; 64:66–72.
69. Blaise D, et al. Prevention of acute GVHD by in vivo use of anti-interleukin-2 receptor
monoclonal antibody (33B3.1): a feasibility trial in 15 patients. Bone Marrow Transplant
1991; 8:105–111.
70. Heslop HE, et al. In vivo induction of gamma interferon and tumor necrosis factor by
interleukin-2 infusion following intensive chemotherapy or autologous marrow transplantation.
Blood 1989; 74:1374–1380.
71. Racadot E, et al. Sequential use of three monoclonal antibodies in corticosteroid-resistant
acute GVHD: a multicentric pilot study including 15 patients. Bone Marrow Transplant
1995; 15:669–677.